Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Cash flow from operating activities
Net loss	$ (31,021)	$ (11,330)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Stock-based compensation expense	3,673	3,573
Depreciation	1,014	1,196
Amortization of premiums and discounts on marketable securities	(998)	(1,931)
Loss on disposal of fixed assets	30	59
Non-cash lease expense	1,221	1,057
Changes in operating assets and liabilities:
Accounts receivable	(119)	79,313
Related party collaboration receivable	189	721
Prepaid expenses and other current assets	868	(794)
Other non-current assets		(15)
Accounts payable	(1,362)	5,975
Accrued expenses	(5,118)	(9,305)
Operating lease liabilities	(1,730)	891
Deferred revenue	(4,542)	(10,643)
Net cash (used in) provided by operating activities	(37,895)	58,767
Cash flow from investing activities
Purchases of property and equipment	(658)	(2,141)
Purchases of marketable securities	(76,924)	(203,852)
Proceeds from sales and maturities of marketable securities	118,783	109,928
Net cash provided by (used in) investing activities	41,201	(96,065)
Cash flow from financing activities
Proceeds from the exercise of stock options	82	78
Proceeds from the issuance of common stock and pre-funded warrants in connection with the underwritten public offering		93,473
Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement		19,305
Net cash provided by financing activities	82	112,856
Net increase in cash, cash equivalents, and restricted cash	3,388	75,558
Cash, cash equivalents, and restricted cash, beginning of period	74,241	70,395
Cash, cash equivalents, and restricted cash, end of period	$ 77,629	145,953
Supplemental disclosure of cash and non-cash activities
Operating lease right-of-use asset obtained in exchange for operating lease liability		$ 26,751